• LAST PRICE
    15.4500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    15.4200/ 1
  • Ask / Lots
    16.0200/ 2
  • Open / Previous Close
    15.4600 / 15.4500
  • Day Range
    Low 15.4500
    High 15.6200
  • 52 Week Range
    Low 11.8300
    High 23.8100
  • Volume
    366,602
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 15.56
TimeVolumeVRNA
09:32 ET396615.5
09:34 ET10015.54
09:36 ET95815.5725
09:38 ET230015.54
09:39 ET1719615.5
09:41 ET16715.5089
09:43 ET260015.54
09:45 ET280015.58
09:52 ET20015.54
09:54 ET10015.54
09:56 ET20015.575
09:59 ET26815.6
10:08 ET142615.62
10:10 ET40315.615
10:12 ET274315.57
10:14 ET44315.55
10:15 ET161315.555
10:21 ET82515.54
10:24 ET40015.53
10:26 ET101015.55
10:28 ET30015.53
10:30 ET10015.52
10:32 ET10015.53
10:33 ET30015.52
10:35 ET180715.52
10:37 ET18915.53
10:42 ET257515.57
10:44 ET42915.57
10:46 ET29915.57
10:48 ET20015.59
10:50 ET20015.5815
10:53 ET69515.6
10:55 ET411115.56
10:57 ET15015.5694
11:00 ET94515.5547
11:02 ET30015.538
11:04 ET165815.59
11:06 ET10015.59
11:09 ET120015.56
11:11 ET70015.51
11:13 ET35015.52
11:18 ET238615.55
11:24 ET212015.57
11:27 ET20015.55
11:29 ET108315.55
11:33 ET10015.54
11:36 ET40015.53
11:40 ET20015.53
11:44 ET42615.54
11:54 ET10015.535
11:56 ET148815.53
11:58 ET1641215.518
12:02 ET1825515.5
12:03 ET62915.52
12:07 ET77515.52
12:09 ET40015.51
12:12 ET10015.52
12:20 ET10015.51
12:21 ET10015.53
12:23 ET117415.55
12:25 ET10015.558
12:27 ET111215.53
12:30 ET60015.51
12:36 ET220915.52
12:38 ET10015.53
12:48 ET10015.525
12:52 ET10015.54
12:54 ET60015.518
12:56 ET10015.52
01:03 ET190115.52
01:06 ET60015.5
01:10 ET40015.51
01:14 ET10015.5
01:15 ET90015.52
01:17 ET802415.555
01:19 ET10015.56
01:21 ET159515.54
01:24 ET164015.55
01:26 ET90015.56
01:28 ET10015.55
01:30 ET20015.55
01:37 ET50015.54
01:39 ET19015.5399
01:44 ET20015.53
01:48 ET78115.54
01:50 ET71415.53
01:55 ET84115.56
02:04 ET52615.55
02:08 ET1423415.5
02:13 ET231015.51
02:18 ET10015.51
02:20 ET10015.51
02:22 ET27515.5
02:24 ET40015.52
02:26 ET110815.51
02:29 ET10015.51
02:31 ET20015.5
02:36 ET30015.52
02:38 ET10015.52
02:40 ET10015.52
02:42 ET20015.53
02:45 ET50015.54
02:47 ET78615.53
02:49 ET60015.52
02:51 ET150015.5
02:54 ET10015.52
02:56 ET20015.51
03:00 ET40015.51
03:02 ET51615.52
03:03 ET50015.51
03:09 ET94315.53
03:12 ET72215.52
03:14 ET54615.52
03:16 ET65915.53
03:18 ET10015.535
03:21 ET104015.54
03:23 ET10015.53
03:25 ET10015.53
03:27 ET40015.54
03:30 ET1373615.51
03:32 ET278915.48
03:34 ET159115.51
03:36 ET28915.48
03:38 ET181115.48
03:41 ET30015.485
03:43 ET30015.49
03:45 ET10015.49
03:48 ET73715.5
03:50 ET75915.5
03:52 ET120015.5
03:54 ET102615.47
03:56 ET221915.46
03:57 ET971015.45
03:59 ET2175515.45
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVRNA
Verona Pharma PLC
1.2B
-22.5x
---
United StatesBLTE
Belite Bio Inc
1.2B
-32.7x
---
United StatesSYRE
Spyre Therapeutics Inc
1.2B
-0.4x
---
United StatesCGEM
Cullinan Therapeutics Inc
1.2B
-7.3x
---
United StatesGYRE
Gyre Therapeutics Inc
1.3B
-0.8x
---
United StatesSRRK
Scholar Rock Holding Corp
1.1B
-7.4x
---
As of 2024-05-01

Company Information

Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual inhibition enables it to act as a bronchodilator and a non-steroidal anti-inflammatory agent . It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.

Contact Information

Headquarters
Riverside, 3 More London PlaceLONDON, United Kingdom SE1 2RE
Phone
203-283-4200
Fax
207-863-3314

Executives

Non-Executive Independent Chairman of the Board
David Ebsworth
President, Chief Executive Officer, Executive Director
David Zaccardelli
Chief Financial Officer
Mark Hahn
General Counsel
Claire Poll
Chief Medical Officer
Kathleen Rickard

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.2B
Revenue (TTM)
$0.00
Shares Outstanding
10.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.43
EPS
$-0.69
Book Value
$3.10
P/E Ratio
-22.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.